Fredrick Allain
John Simon Craw
Dr Kamal Azzaoui
Saverna Therapeutics’ main aim is to discover and develop new molecules for therapeutically areas such inflammation, oncology and infectious diseases. They use a platform based on Fragment Screening using NMR coupled with Machine Learning to identify molecules targeting none coding RNAs.
Dr John Schneekloth
Dr Michal Minczuk
Dr Pawel Sledz
Dr Pawel Sledz is interested in structure-based development of small molecules to combat cancer, in particular targeting proteins involved in epitranscriptomic and epigenetic regulation. Postranscriptional modifications of RNA constitute a novel and very exciting opportunity for drug discovery, particularly in oncology. His team pioneered structural and chemical biology studies of m6A-modification machinery, and leveraged on these findings to develop chemical probes targeting m6A-relevant protein targets (protein-RNA interactions and RNA-modifying proteins), active in the cellular models of cancer.
Professor François Fuks
Dr Barak Akabayov
